Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer
Neurol 91:e985-e994, Touat, M.,et al, 2018
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Inflammatory Myopathies with Anti-Ku Antibodies
Medicine 91:95-102, Rigolet,A.,et al, 2012
Polymyositis and Dermatomyositis
Lancet 362:971-982, Dalakas,M.C.&Hohlfeld,R., 2003
Treatment of Inflammatory Myopathies
Muscle & Nerve 20:651-664997., Mastaglia,F.L.,et al, 1997
Drug Therapy of Idiopathic Inflammatory Myopathies:Response to Prednisone Azathioprine, & Methotrexate
Am J Med 94:379-387, Joffe,M.M.,et al, 1993
The Idiopathic Inflammatory Myopathies and Their Treatment
JNNP 54:285-287, Walton,J., 1991
Polymyositis, Dermatomyositis, and Inclusion-Body Myositis
NEJM 325:1487-1498, Dalakas,M.C., 1991
Current Concepts in the Idiopathic Inflammatory Myopathies:Polymyositis, Dermatomyositis, and Related Disorders
Ann Int Med 111:143-157, Plotz,P.H.,et al, 1989
Neuropsychiatric Manifest. of SLE:Diagnosis, Clinical Spectrum, & Relationship to Other Features of the Disease
Medicine 55:323, Feinglass,E.J.,et al, 1976
Polymyositis & Dermatomyositis
NEJM 292:344, 1975, 292:403975., Bohan,A.,et al, 1975
Clinicopathologic Conference, Granulomatosis with Polyangiitis
NEJM 379:2452-2461, Case 39-2018, 2018
Inflammatory Muscle Diseases
NEJM 372:1734-1747, Dalakas, M.C., 2015
The Spectrum of Statin Myopathy
Curr Opin Rheumatol 25:747-752, Mohassel, P. & Mammen, A.L., 2013
Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013
Evaluation and Treatment of Inflammatory Myopathies
JNNP 80:1060-1068, Amato,A. &Barohn,R.J., 2009
Fatal Myositis Due to the Microsporidian Brachiola algerae, a Mosquito Pathogen
NEJM 351:42-47, Coyle,C.M.,et al, 2004
The Neurologic Complications of Scleromyxedema
Medicine 80:313-319, Berger,J.R.,et al, 2001
Focal, Steroid Responsive Myositis Causing Dropped Head Syndrome
Muscle & Nerve 22:769-771, Biran,I.,et al, 1999
A Sartorial Challenge
Lancet 354:996, Reading,P.J.,et al, 1999
Acute Rectus Muscle Palsy in Children as a Result of Orbital Myositis
J Pediatr 128:230-233, Pollard,F.,et al, 1996
Common Variable Immunodeficiency and Inclusion Body Myositis:A Distinct Myopathy Mediated by Natural Killer Cells
Ann Neurol 37:806-810, Dalakas,M.C.&Illa,I., 1995
Treatment of Inclusion-Body Myositis with High-Dose Intravenous Immunoglobulin
Neurol 43:876-879, Soueidan,S.A.&Dalakas,M.C., 1993
Generalized Myositis in Behcet Disease:TReatment with Cyclosporine
Ann Int Med 116:651-653, Lingenfelser,T.,et al, 1992
Immunologic Aspects of Neurological and Neuromuscular Diseases
JAMA 268:2918-2922, Zweiman,B.&Levinson,A.I., 1992
Inclusion Body Myositis, Observations in 40 Patients
Brain 112:727-747, Lotz,B.P.,et al, 1989
Myositis of Chronic Graft Versus Host Disease
Neurol 33:1222-1224, Reyes,M.G.,et al, 1983
Presentation, Treatment, & Prognosis of Idiopathic Inflammatory Muscle Disease in a Rural Hospital
Am J Med 75:433-438, Hoffman,G.S.,et al, 1983
Childhood Dermatomyositis:Factors Predicting Functional Outcome and Development of Dystrophic Calcification
Pediatrics 103:882-888, Bowyer,L.S.,et al, 1983
Successful Treat. of Echovirus Meningoenceph & Myo Fasciitis With Immune Glob Therapy In X-Linked Agammaglob
NEJM 304:1278-1281, Mease,P.J.,et al, 1981
Alternating Proptosis
Arch Neurol 34:642, Keane,J.R., 1977